{"address1": "2855 Gazelle Court", "city": "Carlsbad", "state": "CA", "zip": "92010", "country": "United States", "phone": "760 931 9200", "website": "https://www.ionis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.", "fullTimeEmployees": 1069, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brett P. Monia Ph.D.", "age": 63, "title": "Founder, CEO & Director", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 2383246, "exercisedValue": 2375238, "unexercisedValue": 952741}, {"maxAge": 1, "name": "Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.", "age": 62, "title": "Executive VP of Finance & CFO", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1143668, "exercisedValue": 2283863, "unexercisedValue": 358691}, {"maxAge": 1, "name": "Dr. Richard S. Geary Ph.D.", "age": 66, "title": "Executive VP & Chief Development Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1013813, "exercisedValue": 1051560, "unexercisedValue": 341387}, {"maxAge": 1, "name": "Dr. Eric E. Swayze Ph.D.", "age": 58, "title": "Executive Vice President of Research", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1012585, "exercisedValue": 1360081, "unexercisedValue": 298254}, {"maxAge": 1, "name": "Mr. Darren  Gonzales", "title": "Chief Accounting Officer & Senior VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. C. Frank Bennett BSc, Ph.D.", "age": 67, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 651639, "exercisedValue": 1367979, "unexercisedValue": 2986721}, {"maxAge": 1, "name": "Mr. D. Wade Walke Ph.D.", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick R. O'Neil Esq.", "age": 50, "title": "Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 815692, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy  Berns J.D.", "title": "Senior VP and Chief Compliance & Quality Assurance Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Hayley  Soffer", "title": "Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 3, "compensationRisk": 1, "shareHolderRightsRisk": 5, "overallRisk": 3, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-irhome", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 30.17, "open": 30.17, "dayLow": 27.195, "dayHigh": 30.17, "regularMarketPreviousClose": 30.17, "regularMarketOpen": 30.17, "regularMarketDayLow": 27.195, "regularMarketDayHigh": 30.17, "payoutRatio": 0.0, "beta": 0.279, "forwardPE": -7.28877, "volume": 3017068, "regularMarketVolume": 3017068, "averageVolume": 1652023, "averageVolume10days": 1620340, "averageDailyVolume10Day": 1620340, "bid": 27.22, "ask": 27.34, "bidSize": 7, "askSize": 3, "marketCap": 4333385728, "fiftyTwoWeekLow": 27.195, "fiftyTwoWeekHigh": 52.34, "priceToSalesTrailing12Months": 6.1454434, "fiftyDayAverage": 32.4296, "twoHundredDayAverage": 39.21075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3989241600, "profitMargins": -0.6437, "floatShares": 157589727, "sharesOutstanding": 158964992, "sharesShort": 12814848, "sharesShortPriorMonth": 12673485, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0806, "heldPercentInsiders": 0.00833, "heldPercentInstitutions": 1.05067, "shortRatio": 6.9, "shortPercentOfFloat": 0.094, "impliedSharesOutstanding": 158964992, "bookValue": 3.726, "priceToBook": 7.316157, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -453896992, "trailingEps": -3.04, "forwardEps": -3.74, "enterpriseToRevenue": 5.657, "enterpriseToEbitda": -8.614, "52WeekChange": -0.37734127, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 27.26, "targetHighPrice": 78.0, "targetLowPrice": 37.0, "targetMeanPrice": 58.602, "targetMedianPrice": 60.0, "recommendationMean": 1.92, "recommendationKey": "buy", "numberOfAnalystOpinions": 25, "totalCash": 2302918912, "totalCashPerShare": 14.487, "ebitda": -463131008, "totalDebt": 1958781056, "quickRatio": 7.743, "currentRatio": 8.471, "totalRevenue": 705137984, "debtToEquity": 332.927, "revenuePerShare": 4.716, "returnOnAssets": -0.09908, "returnOnEquity": -0.93104, "grossProfits": -207607008, "freeCashflow": -352826496, "operatingCashflow": -500947008, "revenueGrowth": -0.302, "grossMargins": -0.29442, "ebitdaMargins": -0.65679, "operatingMargins": -0.48911998, "financialCurrency": "USD", "symbol": "IONS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 674487000000, "preMarketChange": 0.069999695, "preMarketChangePercent": 0.2567854, "preMarketPrice": 27.33, "marketState": "PRE", "regularMarketChangePercent": -9.645343, "regularMarketPrice": 27.26, "shortName": "Ionis Pharmaceuticals, Inc.", "longName": "Ionis Pharmaceuticals, Inc.", "regularMarketChange": -2.9099998, "regularMarketDayRange": "27.195 - 30.17", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1652023, "fiftyTwoWeekLowChange": 0.065000534, "fiftyTwoWeekLowChangePercent": 0.0023901649, "fiftyTwoWeekRange": "27.195 - 52.34", "fiftyTwoWeekHighChange": -25.08, "fiftyTwoWeekHighChangePercent": -0.4791746, "fiftyTwoWeekChangePercent": -37.734127, "earningsTimestamp": 1739966400, "earningsTimestampStart": 1746448200, "earningsTimestampEnd": 1746793800, "earningsCallTimestampStart": 1739982600, "earningsCallTimestampEnd": 1739982600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.04, "epsForward": -3.74, "epsCurrentYear": -2.82083, "priceEpsCurrentYear": -9.663822, "fiftyDayAverageChange": -5.1695995, "fiftyDayAverageChangePercent": -0.15940991, "twoHundredDayAverageChange": -11.95075, "twoHundredDayAverageChangePercent": -0.30478248, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.9 - Buy", "corporateActions": [], "preMarketTime": 1743595514, "regularMarketTime": 1743537602, "exchange": "NMS", "messageBoardId": "finmb_30300", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Ionis Pharmaceuticals", "trailingPegRatio": null}